Table 11 Anticancer activity of synthesized compounds against HeLa, IMR-32 & MCF-7 cancer cells using MTT assay [53]
From: Therapeutic potential of oxadiazole or furadiazole containing compounds
Compound | R1 | R2 | IC50 (μM)*(HeLa) | IC50 (μM)*(IMR-32) | IC50 (μM)* (MCF-7) |
|---|---|---|---|---|---|
Isatin | Â | Â | 521.9 | 352.74 | 410.95 |
17 | Intermediate | Â | 309.59 | 176.85 | 206.95 |
17a | H | H | 25.47 | 30.65 | 33.62 |
17b | F | H | 11.99 | 13.48 | 15.57 |
17c | Cl | H | 12.84 | 15.84 | 16.68 |
17d | Br | H | 10.64 | 12.68 | 16.06 |
17e | CH3 | H | 22.59 | 27.25 | 29.38 |
17f | NO2 | H | 18.60 | 22.51 | 24.48 |
17Â g | COOH | H | 17.25 | 20.85 | 22.95 |
17Â h | H | Cl | 18.69 | 22.51 | 24.92 |
17i | H | NO2 | 16.20 | 19.35 | 20.38 |
17j | H | CH3 | 15.12 | 18.32 | 20.95 |
17Â k | H | COOH | 20.36 | 24.28 | 25.98 |
17Â l | H | COOCH3 | 19.32 | 23.85 | 25.18 |
Cisplatin | Â | Â | 14.08 | 13.64 | 13.54 |